AngioDynamics Prints Its Cleanest Quarter in Years — Right as the Stock Falls 28% and the CEO Walks Out the Door
MedTech is now 49% of revenue, gross margin jumped 410bp, and a $1.9B BPH option just got sized — but the tape and a leadership handoff say the market isn't buying the victory lap.
ANGO · Earnings Call · 2026-10-08
The victory lap nobody is applauding
On the page, AngioDynamics's fiscal Q1 was the cleanest quarter the company has printed in years. Revenue rose to $80.9M, up roughly 7% year over year. The MedTech platforms — Auryon, the mechanical thrombectomy franchise, NanoKnife — grew 13.2% and now represent 49% of the total, up from 47% a year ago. Gross margin leapt to 59.4%, a 410-basis-point improvement, powered by pricing, the ongoing mix shift toward higher-margin MedTech, and a $1.2M tariff refund. Adjusted net loss narrowed to $0.04 a share from $0.10. CEO Jim Clemmer called it “clear evidence that the strategy guiding our transformation over the past several years keeps paying off” — James C. Clemmer, Chief Executive Officer · 2026-10-08.
Then there is the tape. The stock sits roughly 30% below its August 31 peak of $16.13 after a brutal nine-day slide of about 28%, and the shares carry a full-history return of −29.6% with a 63.7% drawdown from their 2021 high of $30.97. For a $488M market-cap name, a quarter this good landing into a tape this bad is the whole story: either the market is pricing something the income statement hasn't caught up to, or the equity has simply been re-rated around the uncertainty sitting right next to the results.
A handoff at the top
The something is partly a change of command. After a decade building what he calls a transformed company, Clemmer is handing the keys over.
Our board has completed a comprehensive search for my successor. I am pleased to share that Eric Honer will be joining us as President and Chief Executive Officer effective November 2.
Honer comes from Getinge, where he ran a $1.2B North American business, with prior stints at Abbott Vascular, Becton Dickinson and Boston Scientific — exactly the endovascular and urology pedigree AngioDynamics sells into.
The nuance investors must weigh: the operating story is now a pure execution story, and execution stories hinge on continuity. Management's own framing — “This all comes back to patients first” — James C. Clemmer, Chief Executive Officer · 2026-10-08 — is strategy-as-mission, and the outgoing CEO's sign-off insisted the results were deliberate: “What you heard here today is not an accident, and it is not random.” — James C. Clemmer, Chief Executive Officer · 2026-10-08 A new CEO inherits a portfolio mid-ramp, with the reimbursement build-out for NanoKnife and the AlphaReturn IDE readout still ahead — the two biggest catalysts on the board — and it is fair for the market to demand a discount until Honer's priorities are visible.
The long arc also matters. Revenue has drifted down on a ten-year view, a shape that peaked near $90M back in 2016, and gross profit has been similarly flat for ten years. Translation: the mix shift is not cosmetic. It is the only mechanism that has historically moved this company's margin structure.
The crack in mechanical thrombectomy
The most telling line in the release didn't come from the growth engines — it came from the franchise the company spent the last two years bragging about. Combined AngioVac and AlphaVac sales were $12M, up just 6.7%. The split is the drama: AlphaVac grew 37.4% to $4.5M, while AngioVac fell 5.9% year over year to $7.5M. Management dressed it in soft language — AngioVac is “working through a tougher comp right now but the underlying demand for the product remains strong” — James C. Clemmer, Chief Executive Officer · 2026-10-08 — and guided it to single-digit growth while AlphaVac carries the segment.
That is a meaningful departure from the prior call, when AngioVac was cast as a co-star, not a laggard. In July, Clemmer admitted the miss candidly: “AngioVac for the year would've been single digits. It was. We still wanted to do a bit more there.” — Jim Clemmer, Chief Executive Officer · 2026-07-14 What the company is really betting on is the AlphaReturn blood-management add-on — the missing feature the market has been conditioned to expect — which the CFO framed as removing the last objection. Until AlphaReturn clears its IDE, mechanical thrombectomy is a two-speed business: one platform accelerating, one stalling. The repeated emphasis on getting products into the hands of physicians and shifting toward higher-acuity office-based labs is not new rhetoric — it is the same playbook, and the market has heard it before.
What is genuinely new: BPH, and the tariff tailwind
Two items are new enough to matter. First, NanoKnife's disposable sales grew 24.1% and total NanoKnife revenue rose 29%, but the capital line (+53.5%) is the noisy part, and the CFO was quick to cap expectations: “capital sales are always lumpy quarter to quarter, so we would not expect capital to grow at this rate going forward.” — Stephen A. Trowbridge, Executive Vice President and Chief Financial Officer · 2026-10-08 The real news is the platform opportunity in BPH. FDA approval of the RELIEF study opens a market the company now sizes at roughly $1.9 billion — a concrete number management explicitly declined to give just one quarter ago, when Clemmer said “We haven't yet sized the market or talked about that beyond this yet.” — Jim Clemmer, Chief Executive Officer · 2026-07-14 That is a fresh, company-unique catalyst layered on top of the still-unfinished prostate cancer reimbursement build-out.
Second, the tariff refund is a small number tied to a very big market conversation. AngioDynamics booked $1.2M of refunds for a net ~$400K benefit, and the keyword tariff refund now sits among the company's top themes — right as net tariff refunds and refund-related language dominate the entire market's keyword board across quarters. This is a rare case where a micro-cap's line item is riding a macro wave rather than a self-generated story, and absent the refund the margin would have been 57.8% — still strong, but the optics matter.
The financial backbone is intact. The company ended with $34M of cash, a debt-free balance sheet, and a net cash position of about $76M. It used $15.3M of operating cash in the quarter — seasonal, management insists — while reaffirming positive full-year operating cash flow, with free cash flow now firmly positive and R&D running near 10% of sales.
The bottom line
AngioDynamics just executed the quarter its strategy has promised for years — and the market sold it. The valuation is not stretched on a sales basis, at roughly 1.7x revenue after a 42% derating over the past year, so the sell-off looks less like a valuation reset than a confidence gap: a CEO handoff, a cracking legacy franchise, and catalysts (AlphaReturn, BPH) that sit in the future tense. The bulls get a clean P&L, a debt-free balance sheet, and a newly sized $1.9B option; the bears get a decade of flat revenue, an AngioVac that has gone from asset to asterisk, and a leadership transition at the exact moment execution can least afford a hesitation. That tension — not the headline beat — is what the next two quarters will resolve.